Clinical Development Research Targeted Protein Degradation 
The Pharma Data
SEPTEMBER 25, 2020
ICR and Cancer Research UK spinout closes Series B financing. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. Earlier this year, Monte Rosa announced that it had raised an initial £32.5m
The Pharma Data
JULY 22, 2021
The companies will equally share worldwide development costs, commercialization expenses, and profits. This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 21, 2020
Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed. ” About Sosei Heptares.
The Pharma Data
JANUARY 31, 2021
In addition to Metrion, these collaborations with Captor Therapeutics in targeted protein degradation and with PharmEnable to access proprietary artificial intelligence-enabled and medicinal chemistry technologies are a key factor to drive our future growth ambitions.” For more information, please visit [link].
LifeSciVC
FEBRUARY 5, 2025
However, in recent years, huge leaps have been made in drug discovery ranging from novel technologies unearthing new techniques for small molecule development to new modalities like targeted protein degradation that are beginning to open the door to a promising wave of transcription factor-directed therapeutic candidates.
Expert insights. Personalized for you.
40 
Let's personalize your content